BusinessMelinta Therapeutics Provides for Distribution of Delafloxacin to 19 Countries via Extended Agreement with Eurofarma LaboratóriosBy Nasdaq OMXSep 26, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics Presenting Detailed Analyses from Baxdela Phase 3 ABSSSI Trials and In Vitro Performance against Isolates of Resistant CABP and other InfectionsBy Nasdaq OMXSep 25, 2017, 12:01 PM UTC
BusinessMelinta Therapeutics to Participate in Two Upcoming Investor ConferencesBy Nasdaq OMXSep 22, 2017, 12:00 PM UTC
BusinessMelinta Therapeutics Publication Highlights Baxdela Activity Against Fluoroquinolone-Non-Susceptible MRSA PathogensBy Nasdaq OMXSep 18, 2017, 12:01 PM UTC
BusinessAccelerate Diagnostics Reports Q2 2017 Financial Results, Doubles Revenue Generating PlacementsBy Nasdaq OMXAug 3, 2017, 8:00 PM UTC
BusinessAccelerate Diagnostics Welcomes Dr. Romney Humphries as Chief Scientific OfficerBy Nasdaq OMXJul 31, 2017, 11:30 AM UTC
BusinessAccelerate Diagnostics Schedules Call to Review Second Quarter 2017 Results for August 3rdBy Nasdaq OMXJul 18, 2017, 9:38 PM UTC
BusinessMelinta Therapeutics Announces U.S. FDA Approval of Baxdela™ (Delafloxacin) for Acute Bacterial Skin and Skin Structure Infections (ABSSSI)By Nasdaq OMXJun 19, 2017, 8:30 PM UTC
